RNA疫苗

摘要

Nucleic acid vaccines consist of plasmid DNA,viral vectors and RNA vaccines.Since the nucleic acid vaccines combine the benefits of live-attenuated vaccines,and avoid the problems of complication related to live-attenuated vaccine safety and production,they may change the way that next generation vaccines are produced.RNA vaccines,including those based on messenger RNA (mRNA) and self-amplifying RNA replicons,have the potential to break through the limitations of plasmid DNA and viral vectors.With solving the issue of cost and manufacturing feasibility,the commercialization of RNA vaccines has become promising.The concept of RNA vaccines has been demonstrated in humans,and the prospects for further development into commercial products are very encouraging.%核酸疫苗包括质粒DNA、病毒载体和RNA疫苗,极有可能促成新一代疫苗生产方式的变革,因为它既综合了减毒活疫苗的优势,又避免了减毒活疫苗的安全性及生产复杂性等问题.RNA疫苗,包括基于信使RNA(mRNA)和自我扩增RNA复制子的疫苗,能克服质粒DNA和病毒载体的局限性.随着RNA疫苗的生产可行性及成本问题的解决,RNA疫苗商业化的曙光已经显现.RNA疫苗概念在人体中已得到验证,其进一步开发为商业化产品的前景令人鼓舞.